专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO2004092195A3 DENDRITIC CELL BINDING PROTEINS AND USES THEREOF 审中-公开
标题翻译：细胞结合蛋白及其用途
公开(公告)号：WO2004092195A3
公开(公告)日：2005-06-02
申请号：PCT/US2004010832
申请日：2004-04-08
申请人： UNIV TULANE , MOHAMADZADEH MANSOUR , CURIEL TYLER , MORRIS CINDY
发明人： MOHAMADZADEH MANSOUR , CURIEL TYLER , MORRIS CINDY
IPC分类号： A61K38/00 , C07K20060101
CPC分类号： C07K7/08 , A61K38/00 , A61K39/12 , A61K39/29 , A61K2039/5154 , A61K2039/523 , A61K2039/57 , C07K2319/00 , C12N2770/24234
摘要： The present invention provides novel peptides which specifically targets and binds to dendritic cells. Also provided are fusion compositions comprising these peptides and a non-dendritic protein of fragments thereof. Further provided are DNA sequences encoding these peptides and fusion compositions. Methods of using the peptides or fusion compositions to promote an immune response in an individual via administration also are provided.
摘要翻译：本发明提供了特异性靶向并结合树突状细胞的新型肽。还提供了包含这些肽和其片段的非树突状蛋白质的融合组合物。还提供了编码这些肽和融合组合物的DNA序列。还提供了使用肽或融合组合物通过给药在个体中促进免疫应答的方法。

32. 发明申请

WO2005042698A2 T CELL EPITOPES USEFUL IN A HEPATITIS C VIRUS VACCINE AND AS DIAGNOSTIC TOOLS AND METHODS FOR IDENTIFYING SAME 审中-公开
标题翻译：乙型肝炎病毒疫苗和诊断工具中使用的T细胞抗原决定因子及其鉴别方法
公开(公告)号：WO2005042698A2
公开(公告)日：2005-05-12
申请号：PCT/US2004/033942
申请日：2004-10-15
申请人： PECOS LABS, INC. , LUND, Ole , LUNDEGAARD, Claus , NIELSEN, Morten , WORNING, Peder , DEANS, Robert, J. , BUUS, Søren , BRUNAK, Søren
发明人： LUND, Ole , LUNDEGAARD, Claus , NIELSEN, Morten , WORNING, Peder , DEANS, Robert, J. , BUUS, Søren , BRUNAK, Søren
IPC分类号： C12N
CPC分类号： A61K39/29 , A61K39/12 , A61K2039/53 , A61K2039/57 , C07K14/005 , C12N2770/24222 , C12N2770/24234
摘要： In a first aspect the present invention consists of T cell epitopes in the Hepatitis C virus genome. More specifically there is provided 429 linear peptide epitopes from the Hepatitis C Virus genome. In a second aspect the invention also consists of variants of these sequences. In a third aspect this invention consists of a method to predict these sequences from genome data and to validate the predictions experimentally. Ina fourth aspect the present invention provides compositions including these epitopes for use in a vaccine and to induce a T cell response in a subject, or as a diagnostic tool. Figure 2 shows a plot of the measured versus the predicted binding affinity score for four different prediction methods (1) Rammensee matrix method, (b) Hidden Markov model trained on sequences in the Rammensee dataset, (c) Neural network trained with sparse sequence encoding, and (d) The Comb-II neural network method.
摘要翻译：在第一方面，本发明由丙型肝炎病毒基因组中的T细胞表位组成。更具体地，提供了来自丙型肝炎病毒基因组的429个线性肽表位。在第二方面，本发明也由这些序列的变体组成。在第三方面，本发明包括从基因组数据预测这些序列并通过实验来验证预测的方法。在第四方面，本发明提供了包含用于疫苗的这些表位并诱导受试者的T细胞应答或作为诊断工具的组合物。图2显示了四种不同预测方法的测量与预测的结合亲和度得分的曲线图（1）Rammensee矩阵法，（b）针对Rammensee数据集中序列训练的隐马尔可夫模型，（c）用稀疏序列编码训练的神经网络，（d）Comb-II神经网络方法。

33. 发明申请

WO2005005625A3 METHOD FOR INDUCING HEPATITIS C VIRUS (HCV) REPLICATION IN VITRO, CELLS AND CELL LINES ENABLING ROBUST HCV REPLICATION AND KIT THEREFOR 审中-公开
标题翻译：用于诱导病毒，细胞和细胞系中的HEPATITIS C病毒（HCV）复制的方法启动稳定的HCV复制和其他工具
公开(公告)号：WO2005005625A3
公开(公告)日：2005-04-07
申请号：PCT/CA2004001009
申请日：2004-07-14
申请人： UNIV MCGILL , SONENBERG NAHUM , LOPEZ LASTRA MARCELO
发明人： SONENBERG NAHUM , LOPEZ LASTRA MARCELO
IPC分类号： A61K39/29 , C07K14/18 , C12N7/00 , C12N7/02 , C12N5/06 , C12Q1/70 , G01N33/50
CPC分类号： C07K14/005 , A61K39/12 , A61K39/29 , A61K2039/5154 , A61K2039/5156 , C12N7/00 , C12N2770/24221 , C12N2770/24222 , C12N2770/24234 , C12N2770/24251
摘要： The present invention relates to hepatitis C virus (HCV). More particularly, the invention relates to the development of a tool suitable for the search, discovery and validation of novel HCV antiviral drugs and therapies (e.g. vaccine). The invention further relates to methods for inducing HCV replication in vitro, and more particularly to a simple in vitro replication assay for HCV. In addition, the invention relates to the use of the methods of the present invention to prognose the resistance/sensitivity of a particular strain of HCV to a chosen anti-HCV agent. In one embodiment, the present invention relates to an adaptation of a therapeutic regimen for a patient infected with HCV which takes into account the resistance/sensitivity phenotype of the HCV strain which infects same. The invention more particularly, relates to a method for generating an established cell line which produces hepatitis C virus (HCV) comprising transforming peripheral blood mononuclear cells (PBMCs) which produce HCV with Epstein Barr virus (EBV). The invention also relates to an EBV established B-cell line capable of replicating complete and infectious HCV. As well, the invention relates to a cell-based in vitro replication system for HCV comprising an EBV-transformed B-cell capable of replicating complete and infectious HCV, and a second cell population having HCV tropism and in which robust HCV replication occurs, so that under appropriate culture conditions the second cell population can become infected by the infectious HCV produced by the EBV-transformed B-cell. The present invention also relates to kits for transforming a HCV-producing cell and to kits for diagnosing HCV in a patient.
摘要翻译：本发明涉及丙型肝炎病毒（HCV）。更具体地说，本发明涉及适用于新型HCV抗病毒药物和疗法（例如疫苗）的检索，发现和验证的工具的开发。本发明还涉及在体外诱导HCV复制的方法，更具体地涉及用于HCV的简单体外复制测定。此外，本发明涉及本发明的方法用于预测HCV特定菌株对所选抗HCV药物的抗性/敏感性的用途。在一个实施方案中，本发明涉及对感染HCV的患者的治疗方案的适应性，其考虑了感染HCV的HCV毒株的抗性/敏感性表型。本发明更具体地涉及产生产生丙型肝炎病毒（HCV）的建立的细胞系的方法，其包括用Epstein Barr病毒（EBV）转化产生HCV的外周血单核细胞（PBMC）。本发明还涉及能够复制完整和感染性HCV的EBV建立的B细胞系。本发明还涉及一种用于HCV的基于细胞的体外复制系统，其包含能够复制完整和感染性HCV的EBV转化的B细胞，以及具有HCV向性的第二细胞群，其中发生强烈的HCV复制，因此在适当的培养条件下，第二细胞群可以被EBV转化的B细胞产生的感染性HCV感染。本发明还涉及用于转化HCV产生细胞的试剂盒和用于诊断患者HCV的试剂盒。

34. 发明申请

WO2005005625A2 METHOD FOR INDUCING HEPATITIS C VIRUS (HCV) REPLICATION IN VITRO, CELLS AND CELL LINES ENABLING ROBUST HCV REPLICATION AND KIT THEREFOR 审中-公开
标题翻译：用于诱导体外，细胞和细胞系中丙型肝炎病毒（HCV）复制的方法，其使得强有力的HCV复制和试剂盒成为可能
公开(公告)号：WO2005005625A2
公开(公告)日：2005-01-20
申请号：PCT/CA2004/001009
申请日：2004-07-14
申请人： MCGILL UNIVERSITY , SONENBERG, Nahum , LOPEZ LASTRA, Marcelo
发明人： SONENBERG, Nahum , LOPEZ LASTRA, Marcelo
IPC分类号： C12N7/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/29 , A61K2039/5154 , A61K2039/5156 , C12N7/00 , C12N2770/24221 , C12N2770/24222 , C12N2770/24234 , C12N2770/24251
摘要： The present invention relates to hepatitis C virus (HCV). More particularly, the invention relates to the development of a tool suitable for the search, discovery and validation of novel HCV antiviral drugs and therapies (e.g. vaccine). The invention further relates to methods for inducing HCV replication in vitro, and more particularly to a simple in vitro replication assay for HCV. In addition, the invention relates to the use of the methods of the present invention to prognose the resistance/sensitivity of a particular strain of HCV to a chosen anti-HCV agent. In one embodiment, the present invention relates to an adaptation of a therapeutic regimen for a patient infected with HCV which takes into account the resistance/sensitivity phenotype of the HCV strain which infects same. The invention more particularly, relates to a method for generating an established cell line which produces hepatitis C virus (HCV) comprising transforming peripheral blood mononuclear cells (PBMCs) which produce HCV with Epstein Barr virus (EBV). The invention also relates to an EBV established B-cell line capable of replicating complete and infectious HCV. As well, the invention relates to a cell-based in vitro replication system for HCV comprising an EBV-transformed B-cell capable of replicating complete and infectious HCV, and a second cell population having HCV tropism and in which robust HCV replication occurs, so that under appropriate culture conditions the second cell population can become infected by the infectious HCV produced by the EBV-transformed B-cell. The present invention also relates to kits for transforming a HCV-producing cell and to kits for diagnosing HCV in a patient.
摘要翻译：本发明涉及丙型肝炎病毒（HCV）。更具体地说，本发明涉及适用于新型HCV抗病毒药物和治疗（例如疫苗）的搜索，发现和验证的工具的开发。本发明进一步涉及体外诱导HCV复制的方法，更具体地涉及用于HCV的简单体外复制测定。此外，本发明涉及本发明方法的用途，以预测特定HCV株对选定的抗HCV剂的抗性/敏感性。在一个实施方案中，本发明涉及对感染HCV的患者的治疗方案的适应，其考虑了感染HCV的毒株的抗性/敏感性表型。本发明更具体地涉及用于产生产生丙型肝炎病毒（HCV）的已建立的细胞系的方法，其包括转化用EB病毒（EBV）产生HCV的外周血单核细胞（PBMC）。本发明还涉及能够复制完整和感染性HCV的EBV建立的B细胞系。本发明还涉及用于HCV的基于细胞的体外复制系统，其包含能够复制完整和感染性HCV的EBV转化的B细胞和具有HCV嗜性的第二细胞群，并且在发生强烈的HCV复制，从而在适当的培养条件下，第二细胞群体可能被EBV转化的B细胞产生的感染性HCV感染。本发明还涉及用于转化HCV产生细胞的试剂盒和用于诊断患者中的HCV的试剂盒。

35. 发明申请

WO2004024904A3 INFECTIOUS HEPACIVIRUS PSEUDO-PARTICLES CONTAINING FUNCTIONAL E1, E2 ENVELOPE PROTEINS 审中-公开
标题翻译：含有功能性E1，E2包膜蛋白的感染性HEPACIVUSUS假颗粒
公开(公告)号：WO2004024904A3
公开(公告)日：2004-06-03
申请号：PCT/IB0303882
申请日：2003-09-12
申请人： INST NAT SANTE RECH MED , BARTOSCH BIRKE , COSSET FRANCOIS-LOIC
发明人： BARTOSCH BIRKE , COSSET FRANCOIS-LOIC
IPC分类号： G01N33/50 , A61K35/76 , A61K39/29 , A61K48/00 , A61P1/16 , A61P31/14 , C07K14/18 , C12N5/10 , C12N7/00 , C12N7/04 , C12N15/09 , C12N15/86 , C12Q1/02 , C12Q1/68 , C12Q1/70 , G01N33/15 , G01N33/569 , G01N33/576
CPC分类号： A61K39/29 , A61K39/12 , A61K48/00 , A61K2039/5256 , A61K2039/5258 , A61K2039/53 , C07K14/005 , C12N7/00 , C12N2710/16143 , C12N2740/13022 , C12N2740/13023 , C12N2740/13034 , C12N2770/24222 , C12N2770/24223 , C12N2770/24234 , C12N2770/24245 , C12N2810/609 , G01N33/566 , G01N2333/186 , G01N2500/10
摘要： The invention relates to the generation and the use of hepacivirus pseudo-particles containing native functional E1, E2 envelope glycoproteins assembled onto retroviral core particles. These particles are highly infectious and constitute a valid model of hepacivirus viríon.
摘要翻译：本发明涉及组装到逆转录病毒核心颗粒上的含有天然功能性E1，E2包膜糖蛋白的肝炎病毒假颗粒的产生和用途。这些颗粒具有高度传染性，构成hepacivirusviríon的有效模型。

36. 发明申请

WO03035010A2 THYMOSIN AUGMENTATION OF GENETIC IMMUNIZATION 审中-公开
标题翻译：胸腺嘧啶增强遗传免疫
公开(公告)号：WO03035010A2
公开(公告)日：2003-05-01
申请号：PCT/US0234535
申请日：2002-10-28
申请人： RHODE ISLAND HOSPITAL , WANDS JACK R
发明人： WANDS JACK R
IPC分类号： C12N15/09 , A61K38/22 , A61K39/29 , A61K39/39 , A61K48/00 , A61P43/00 , C07K14/18 , A61K
CPC分类号： C07K14/005 , A61K38/00 , A61K38/2292 , A61K39/12 , A61K39/29 , A61K39/39 , A61K2039/53 , A61K2039/545 , A61K2039/55516 , A61K2039/57 , C12N2770/24222 , C12N2770/24234 , A61K2300/00
摘要： This invention describes the use of thymosin to augment cellular immune responses to hepatitis C virus. Methods for immunizing a subject susceptable to hepatitis C virus infection against such infection, comprising administering to the subject one or more polynucleotides encoding one or more hepatitis C virus peptides, in combination with one or more thymosins, are disclosed. Compositions suitable for immunizing against hepatitis C virus, comprising one or more polynucleotides encoding one or more hepatitis C virus peptides, and one or more thymosins, are also disclosed.
摘要翻译：本发明描述了胸腺肽用于增强对丙型肝炎病毒的细胞免疫应答。公开了用于免疫可感染丙型肝炎病毒感染的受试者以预防此类感染的方法，其包括向受试者施用编码一种或多种丙型肝炎病毒肽的一种或多种多核苷酸，以及一种或多种胸腺素。还公开了适用于免疫丙型肝炎病毒的组合物，其包含一种或多种编码一种或多种丙型肝炎病毒肽的多核苷酸和一种或多种胸腺素。

37. 发明申请

WO2003023042A1 REKOMBINANTES MVA MIT DER FÄHIGKEIT ZUR EXPRESSION VON HCV STRUKTUR-ANTIGENEN 审中-公开
标题翻译：符合表达结构HCV抗原的能力重组MVA
公开(公告)号：WO2003023042A1
公开(公告)日：2003-03-20
申请号：PCT/EP2002/009958
申请日：2002-09-05
申请人： GSF-FORSCHUNGSZENTRUM FÜR UMWELT UND GESUNDHEIT GMBH , SUTTER, Gerd , ERFLE, Volker , STAIB, Caroline , WANG, Yuan , LI, Guangdi , ZHU, Lixin
发明人： SUTTER, Gerd , ERFLE, Volker , STAIB, Caroline , WANG, Yuan , LI, Guangdi , ZHU, Lixin
IPC分类号： C12N15/863
CPC分类号： A61K39/29 , A61K39/12 , A61K2039/525 , A61K2039/5256 , A61K2039/57 , C12N15/86 , C12N2710/24143 , C12N2770/24234 , C12N2770/24243
摘要： Die Erfindung betrifft rekombinantes MVA, welches in der Lage ist, HCV-Struktur-Antigene, funktionelle Teile dieser Struktur-Antigene oder Epitope dieser Struktur-Antigene zu exprimieren. Die Erfindung beschreibt weiterhin eine pharmazeutische Zubereitung, die insbesondere in Form einer Vakzine vorliegt und ein rekombinantes MVA gemäss der Erfindung enthält, Eukaryontenzellen, die das erfindungsgemässe rekombinante MVA enthalten sowie verschiedene Verwendungen des rekombinanten MVA, beispielsweise zur Produktion rekombinanter Strukturproteine, zur Herstellung einer pharmazeutischen Zubereitung, die insbesondere zur Therapie und Prophylaxe von HCV-Infektionen und hierdurch verursachter Erkrankungen geeignet ist, Verfahren zur Herstellung von rekombinantem MVA und von rekombinanten HCV-Struktur-Polypeptiden, die von diesem rekombinanten MVA kodiert werden, sowie DNA oder RNA dieses rekombinanten MVA.
摘要翻译：本发明涉及一种重组MVA所有能表达结构HCV抗原，所述结构的抗原或所述结构的抗原的表位的功能部件。本发明进一步涉及一种药物组合物，爱特别是在疫苗的形式，并且包含所述重组MVA雅丁本发明，真核细胞也包含本发明的重组MVA和所述重组MVA的各种用途，例如用于制备重组结构蛋白质，制备药物制剂确实适合于治疗和HCV感染和疾病的预防由此引起。本发明进一步涉及一种用于生产重组MVA和由所述重组MVA编码重组HCV结构多肽的方法，以及所说的重组MVA的DNA或RNA。

38. 发明申请

WO03007986A2 VACCINE FORMULATION POTENTIATED BY THE COMBINATION OF A DNA AND AN ANTIGEN 审中-公开
标题翻译：通过DNA和抗原的组合可能引起的疫苗配方
公开(公告)号：WO03007986A2
公开(公告)日：2003-01-30
申请号：PCT/CU0200005
申请日：2002-07-12
申请人： CT INGENIERIA GENETICA BIOTECH , DUENAS CARRERA SANTIAGO , MORALES GRILLO JUAN , ALVAREZ-LAJONCHERE PONCE DE LE , MUSACCHIO LASA ALEXIS , PAJON FEYT ROLANDO , VINA RODRIGUEZ ARIEL , ALVAREZ OBREGON JULIO C , ACOSTA RIVERO NELSON , MARTINEZ DONATO GILLIAN
发明人： DUENAS CARRERA SANTIAGO , MORALES GRILLO JUAN , ALVAREZ-LAJONCHERE PONCE DE LE , MUSACCHIO LASA ALEXIS , PAJON FEYT ROLANDO , VINA RODRIGUEZ ARIEL , ALVAREZ OBREGON JULIO C , ACOSTA RIVERO NELSON , MARTINEZ DONATO GILLIAN
IPC分类号： A61K39/39 , A61K20060101 , A61K39/29 , A61P31/14 , A61P31/20 , A61K39/12
CPC分类号： A61K39/29 , A61K39/12 , A61K39/292 , A61K2039/53 , A61K2039/55505 , A61K2039/70 , C12N2730/10134 , C12N2770/24234
摘要： The invention relates to a vaccine antigen formulation containing the following main components: a) one or more DNAs that express one or more proteins in the immunised individual and b) a viral antigen, in suitable proportions. The novelty of the invention lies in the potentiating effect exerted by at least one of the components on the immune response generated against the other. The invention also relates to the development of novel formulations that minimise the number of components that can amplify and potentiate the range of immune response against different pathogenic entities and generate combined vaccines against pathogenic entities. Said formulations are suitable for use in the pharmaceutical industry for prophylactic and/or therapeutic purposes in individuals.
摘要翻译：本发明涉及含有以下主要成分的疫苗抗原制剂：a）一种或多种在免疫个体中表达一种或多种蛋白质的DNA，以及b）病毒抗原以合适的比例。本发明的新颖性在于由至少一种组分对另一种产生的免疫应答产生的增强作用。本发明还涉及最小化可以扩增和增强针对不同致病实体的免疫应答范围并且产生抗病原体的组合疫苗的组分数量的新配方的开发。所述制剂适合在制药工业中用于个体的预防和/或治疗目的。

39. 发明申请

WO2002083714A2 METHOD AND SYSTEM FOR OPTIMIZING MULTI-EPITOPE NUCLEIC ACID CONSTRUCTS AND PEPTIDES ENCODED THEREBY 审中-公开
标题翻译：用于优化多抗原核酸构建体和编码的肽的方法和系统
公开(公告)号：WO2002083714A2
公开(公告)日：2002-10-24
申请号：PCT/US2002/009877
申请日：2002-03-28
申请人： EPIMMUNE INC. , SETTE, Alessandro , CHESNUT, Robert , LIVINGSTON, Brian, D. , BAKER, Denise, Marie , NEWMAN, Mark, J. , BROWN, David, H.
发明人： SETTE, Alessandro , CHESNUT, Robert , LIVINGSTON, Brian, D. , BAKER, Denise, Marie , NEWMAN, Mark, J. , BROWN, David, H.
IPC分类号： C07K
CPC分类号： A61K39/29 , A61K39/00 , A61K39/12 , A61K39/21 , A61K39/292 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/57 , A61K2039/70 , C07K14/005 , C07K2319/00 , C12N15/86 , C12N2730/10122 , C12N2730/10134 , C12N2740/16022 , C12N2740/16034 , G06F19/16 , G06F19/18 , G06F19/22 , G06F19/24
摘要： The invention relates to the field of biology. In particular, the invention relates to a method and system for designing optimized multi-epitope vaccines having selected combinations of spacer nucleic acid at the junctions of the multi-epitope constructs encoding a plurality of CTL and/or HTL eoutioe oeotudes so as to minimize the number of junciontal epitopes and provide vaccines with increased immunogenicity.
摘要翻译：本发明涉及生物学领域。具体地说，本发明涉及一种用于设计优化的多表位疫苗的方法和系统，所述多表位疫苗在编码多个CTL和/或HTL蛋白质的多表位结构的连接处具有选择的间隔核酸的组合，以使数目的分枝表位并提供具有增加的免疫原性的疫苗。

40. 发明申请

WO2002081715A1 A TRANSGENIC NON-HUMAN ANIMAL HAVING A DISRUPTION OF AT LEAST ONE ALLELE TO THE CEACAM1 GENE AND METHOD OF MAKING SAME 审中-公开
标题翻译：具有至少一个ALLELE至CEACAM1基因的破坏的转基因非人动物及其制备方法
公开(公告)号：WO2002081715A1
公开(公告)日：2002-10-17
申请号：PCT/CA2002/000469
申请日：2002-04-04
申请人： MCGILL UNIVERSITY , BEAUCHEMIN, Nicole , TURBIDE, Claire , HOLMES, Kathryn, V. , BLAU, Dianna , LETOURNEAU, Stephanie
发明人： BEAUCHEMIN, Nicole , TURBIDE, Claire , HOLMES, Kathryn, V. , BLAU, Dianna , LETOURNEAU, Stephanie
IPC分类号： C12N15/85
CPC分类号： C12N15/8509 , A01K67/0275 , A01K67/0276 , A01K2217/072 , A01K2217/075 , A01K2227/105 , A01K2267/02 , A01K2267/0337 , A61K39/12 , A61K39/29 , A61K2039/525 , A61K2039/543 , C07K14/705 , C07K14/70503 , C12N2503/02 , C12N2770/20034
摘要： The present invention relates to a transgenic animal having a disruption of at least one allele of the Ceacam 1 gene and method of making same. More particularly, the present invention relates to transgenic mouse whose germ cells and somatic cells contain a knockout mutation in DNA encoding CEACAM1 a or CEACAM1 b . In a particular embodiment, mice containing a disruption of at least one of the Ceacam 1 gene present a reduced expression of the CEACAM1 a protein. The present invention also relates to a transgenic mouse comprising a disruption of the Ceacam1 gene wherein the mouse expresses at least a reduced level of CEACAM1 a relative to a corresponding wild-type mouse and methods of making same.
摘要翻译：本发明涉及具有至少一种Ceacam1基因的至少一个等位基因的破坏的转基因动物及其制备方法。更具体地说，本发明涉及其生殖细胞和体细胞在编码CEACAM1α或CEACAM1的DNA中含有敲除突变的转基因小鼠。在一个具体实施方案中，含有至少一种终止角质碱基基因的破坏的小鼠存在CEACAM1α蛋白的降低的表达。本发明还涉及包含Ceacam1基因破坏的转基因小鼠，其中所述小鼠相对于相应的野生型小鼠表达至少降低的CEACAM1α水平及其制备方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式